FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309073090> ?p ?o ?g. }

• W4309073090 abstract "The prognosis for metastatic and recurrent tumors of the central nervous system (CNS) remains dismal, and the need for newer therapeutic targets and modalities is critical. The cell surface glycoprotein B7H3 is expressed on a range of solid tumors with a restricted expression on normal tissues. We hypothesized that compartmental radioimmunotherapy (cRIT) with the anti-B7H3 murine monoclonal antibody omburtamab injected intraventricularly could safely target CNS malignancies.We conducted a phase I trial of intraventricular 131I-omburtamab using a standard 3 + 3 design. Eligibility criteria included adequate cerebrospinal fluid (CSF) flow, no major organ toxicity, and for patients > dose level 6, availability of autologous stem cells. Patients initially received 74 MBq radioiodinated omburtamab to evaluate dosimetry and biodistribution followed by therapeutic 131I-omburtamab dose-escalated from 370 to 2960 MBq. Patients were monitored clinically and biochemically for toxicity graded using CTCAEv 3.0. Dosimetry was evaluated using serial CSF and blood sampling, and serial PET or gamma-camera scans. Patients could receive a second cycle in the absence of grade 3/4 non-hematologic toxicity or progressive disease.Thirty-eight patients received 100 radioiodinated omburtamab injections. Diagnoses included metastatic neuroblastoma (n = 16) and other B7H3-expressing solid tumors (n = 22). Thirty-five patients received at least 1 cycle of treatment with both dosimetry and therapy doses. Acute toxicities included < grade 4 self-limited headache, vomiting or fever, and biochemical abnormalities. Grade 3/4 thrombocytopenia was the most common hematologic toxicity. Recommended phase 2 dose was 1850 MBq/injection. The median radiation dose to the CSF and blood by sampling was 1.01 and 0.04 mGy/MBq, respectively, showing a consistently high therapeutic advantage for CSF. Major organ exposure was well below maximum tolerated levels. In patients developing antidrug antibodies, blood clearance, and therefore therapeutic index, was significantly increased. In patients receiving cRIT for neuroblastoma, survival was markedly increased (median PFS 7.5 years) compared to historical data.cRIT with 131I-omburtamab is safe, has favorable dosimetry and may have a therapeutic benefit as adjuvant therapy for B7-H3-expressing leptomeningeal metastases.clinicaltrials.gov NCT00089245, August 5, 2004." @default.
• W4309073090 created "2022-11-21" @default.
• W4309073090 creator A5010076893 @default.
• W4309073090 creator A5014733785 @default.
• W4309073090 creator A5015396908 @default.
• W4309073090 creator A5028508851 @default.
• W4309073090 creator A5028587910 @default.
• W4309073090 creator A5029385885 @default.
• W4309073090 creator A5034081882 @default.
• W4309073090 creator A5034325765 @default.
• W4309073090 creator A5040567851 @default.
• W4309073090 creator A5042379432 @default.
• W4309073090 creator A5043729995 @default.
• W4309073090 creator A5050136149 @default.
• W4309073090 creator A5050235191 @default.
• W4309073090 creator A5050680844 @default.
• W4309073090 creator A5056191527 @default.
• W4309073090 creator A5056859109 @default.
• W4309073090 creator A5068118481 @default.
• W4309073090 creator A5068928963 @default.
• W4309073090 creator A5074725191 @default.
• W4309073090 creator A5076765953 @default.
• W4309073090 creator A5090132494 @default.
• W4309073090 date "2022-11-12" @default.
• W4309073090 modified "2023-10-13" @default.
• W4309073090 title "Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies" @default.
• W4309073090 cites W1608361415 @default.
• W4309073090 cites W1614553858 @default.
• W4309073090 cites W1966020001 @default.
• W4309073090 cites W2030093928 @default.
• W4309073090 cites W2038060241 @default.
• W4309073090 cites W2045770496 @default.
• W4309073090 cites W2068512864 @default.
• W4309073090 cites W2111733282 @default.
• W4309073090 cites W2113695682 @default.
• W4309073090 cites W2136462971 @default.
• W4309073090 cites W2142084832 @default.
• W4309073090 cites W2150636854 @default.
• W4309073090 cites W2151310238 @default.
• W4309073090 cites W2168779318 @default.
• W4309073090 cites W2243572599 @default.
• W4309073090 cites W2264275593 @default.
• W4309073090 cites W233636008 @default.
• W4309073090 cites W2462749555 @default.
• W4309073090 cites W2611071372 @default.
• W4309073090 cites W2736025025 @default.
• W4309073090 cites W2760852110 @default.
• W4309073090 cites W2766923756 @default.
• W4309073090 cites W2801549608 @default.
• W4309073090 cites W2808090012 @default.
• W4309073090 cites W2890944271 @default.
• W4309073090 cites W2921899029 @default.
• W4309073090 cites W2969013249 @default.
• W4309073090 cites W2971319283 @default.
• W4309073090 cites W3092545853 @default.
• W4309073090 cites W3094641169 @default.
• W4309073090 cites W323673244 @default.
• W4309073090 cites W4296289652 @default.
• W4309073090 doi "https://doi.org/10.1186/s13045-022-01383-4" @default.
• W4309073090 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36371226" @default.
• W4309073090 hasPublicationYear "2022" @default.
• W4309073090 type Work @default.
• W4309073090 citedByCount "12" @default.
• W4309073090 countsByYear W43090730902023 @default.
• W4309073090 crossrefType "journal-article" @default.
• W4309073090 hasAuthorship W4309073090A5010076893 @default.
• W4309073090 hasAuthorship W4309073090A5014733785 @default.
• W4309073090 hasAuthorship W4309073090A5015396908 @default.
• W4309073090 hasAuthorship W4309073090A5028508851 @default.
• W4309073090 hasAuthorship W4309073090A5028587910 @default.
• W4309073090 hasAuthorship W4309073090A5029385885 @default.
• W4309073090 hasAuthorship W4309073090A5034081882 @default.
• W4309073090 hasAuthorship W4309073090A5034325765 @default.
• W4309073090 hasAuthorship W4309073090A5040567851 @default.
• W4309073090 hasAuthorship W4309073090A5042379432 @default.
• W4309073090 hasAuthorship W4309073090A5043729995 @default.
• W4309073090 hasAuthorship W4309073090A5050136149 @default.
• W4309073090 hasAuthorship W4309073090A5050235191 @default.
• W4309073090 hasAuthorship W4309073090A5050680844 @default.
• W4309073090 hasAuthorship W4309073090A5056191527 @default.
• W4309073090 hasAuthorship W4309073090A5056859109 @default.
• W4309073090 hasAuthorship W4309073090A5068118481 @default.
• W4309073090 hasAuthorship W4309073090A5068928963 @default.
• W4309073090 hasAuthorship W4309073090A5074725191 @default.
• W4309073090 hasAuthorship W4309073090A5076765953 @default.
• W4309073090 hasAuthorship W4309073090A5090132494 @default.
• W4309073090 hasBestOaLocation W43090730901 @default.
• W4309073090 hasConcept C126322002 @default.
• W4309073090 hasConcept C150903083 @default.
• W4309073090 hasConcept C159654299 @default.
• W4309073090 hasConcept C194409129 @default.
• W4309073090 hasConcept C203014093 @default.
• W4309073090 hasConcept C207001950 @default.
• W4309073090 hasConcept C2776146153 @default.
• W4309073090 hasConcept C2777807558 @default.
• W4309073090 hasConcept C2779651940 @default.
• W4309073090 hasConcept C2780852908 @default.
• W4309073090 hasConcept C29730261 @default.
• W4309073090 hasConcept C2989005 @default.
• W4309073090 hasConcept C542903549 @default.

• next